Scarica l'app Stockscreener
27.37
0.33%
-0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis started at equal-weight at Morgan Stanley on geographic atrophy market - Seeking Alpha
How to Take Advantage of moves in (APLS) - Stock Traders Daily
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated by Analysts at Morgan Stanley - MarketBeat
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts - Benzinga
Apellis Pharmaceuticals (FRA:1JK) Degree of Operating Lever - GuruFocus.com
Victory Capital Management Inc. Sells 49,960 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - MSN
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback - Investing.com India
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpHere's What Happened - MarketBeat
Apellis reiterates neutral rating, steady stock target on FDA decision By Investing.com - Investing.com UK
GSA Capital Partners LLP Purchases New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
T. Rowe Price Investment Management Reduces Stake in Apellis Pha - GuruFocus.com
Apellis Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | APLS Stock News - StockTitan
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference - The Manila Times
(APLS) Trading Signals - Stock Traders Daily
Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Wellington Management Group LLP Reduces Stake in Apellis Pharmac - GuruFocus.com
HC Wainwright Has Negative Outlook of APLS FY2024 Earnings - MarketBeat
William Blair Issues Pessimistic Forecast for APLS Earnings - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript - MSN
Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - MarketBeat
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise By Investing.com - Investing.com Nigeria
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise - Investing.com
Wells Fargo & Company Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00 - MarketBeat
Old West Investment Management LLC Purchases Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Oppenheimer Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $40.00 - MarketBeat
Needham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00 by Analysts at HC Wainwright - MarketBeat
Bank of America Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00 - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $32.00 by Analysts at Piper Sandler - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlig - GuruFocus.com
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Moves After Q3 Results - GuruFocus.com
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results - citybiz
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday - MSN
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week LowShould You Sell? - MarketBeat
Apellis Pharma stock hits 52-week low at $25.31 amid market challenges - Investing.com Canada
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Apellis stock drops after Q3 miss (APLS:NASDAQ) - Seeking Alpha
47,500 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by AlphaCentric Advisors LLC - MarketBeat
Apellis Q3 Revenue Soars to $196.8M, SYFOVRE Growth Continues Despite Price Adjustments | APLS Stock News - StockTitan
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know - MSN
A Glimpse of Apellis Pharmaceuticals's Earnings Potential - Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Sector Perform" Rating from Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Previ - GuruFocus.com
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Increased to Strong-Buy at Evercore ISI - MarketBeat
Analysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $65.41 - MarketBeat
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):